Nanoplexed Poly I:C BO-112

Phase 1Biologic

JJonsson Comprehensive Cancer Center

Nanoplexed Poly I:C BO-112 is one of 54 biologic programs targeting Soft Tissue Sarcoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Soft Tissue SarcomaActive, not recruiting

Soft Tissue SarcomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

60 competitors in Soft Tissue Sarcoma

#DrugCompanyPhaseTrials

Votrient

Novartis

Approved

14 2

Adriamycin

Pfizer

Phase 3

36 3

Adriamycin

Pfizer

Phase 3

27 4

Lynparza

AstraZeneca

Approved

1 5

Idamycin

Pfizer

Approved

—6

Ifex

BBaxter Healthcare Corporation

Phase 3

32 7

Yondelis

AApotex Inc.

Phase 3

16 8

Treanda

AAzurity Pharmaceuticals

Farydak

Neulasta

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 1Active, not recruiting

Soft Tissue Sarcoma

NCT04420975

Clinical

Trials by Indication[1]

Liver Cancer1 trial

BO-112 and Pembrolizumab for the Treatment of PD-1/PD-L1 Refractory Liver Cancer

Terminated·JJonsson Comprehensive Cancer Center·Phase 1·NCT04777708·1 enrolled

Soft Tissue Sarcoma1 trial

Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma

Active, not recruiting·JJonsson Comprehensive Cancer Center·Phase 1·NCT04420975·14 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Nanoplexed Poly I:C BO-112. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Nanoplexed Poly I:C BO-112 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Nanoplexed Poly I:C BO-112. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jonsson Comprehensive Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: JJonsson Comprehensive Cancer Center

Nanoplexed Poly I:C BO-112

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Liver Cancer1 trial

Soft Tissue Sarcoma1 trial

References

Drug Info

Quick Facts

Related News